In September 2010, the Medicines Patent Pool (MPP) received its first licence from the United States National Institutes of Health (NIH) for patents related to the HIV medicine darunavir (DRV). However, there may be additional patents on darunavir which have not been licensed to MPP.

In addition, the MPP collaborated with Janssen in announcing an expansion of its commitment not to enforce patents on paediatric darunavir in May 2015.